12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Benzinga · 07/30 12:08
Gainers
- Replimune Group (NASDAQ:REPL) stock moved upwards by 73.3% to $6.5 during Wednesday's pre-market session. The company's market cap stands at $291.7 million.
- Capricor Therapeutics (NASDAQ:CAPR) shares moved upwards by 20.47% to $8.12. The company's market cap stands at $308.0 million.
- Sarepta Therapeutics (NASDAQ:SRPT) shares moved upwards by 13.71% to $18.0. The company's market cap stands at $1.5 billion.
- Penumbra (NYSE:PEN) stock moved upwards by 13.58% to $258.0. The company's market cap stands at $8.7 billion. The company's, Q2 earnings came out yesterday.
- Cellectar Biosciences (NASDAQ:CLRB) stock increased by 11.41% to $5.25. The market value of their outstanding shares is at $13.4 million.
- Protagenic Therapeutics (NASDAQ:PTIX) stock increased by 10.74% to $3.4. The market value of their outstanding shares is at $2.6 million.
Losers
- VYNE Therapeutics (NASDAQ:VYNE) stock fell 54.0% to $0.66 during Wednesday's pre-market session. The market value of their outstanding shares is at $23.9 million.
- Healthcare Triangle (NASDAQ:HCTI) shares decreased by 39.38% to $0.03. The company's market cap stands at $20.7 million.
- Mural Oncology (NASDAQ:MURA) stock declined by 21.85% to $1.86. The market value of their outstanding shares is at $41.0 million.
- Cardiff Oncology (NASDAQ:CRDF) shares decreased by 21.16% to $2.61. The market value of their outstanding shares is at $220.2 million. The company's, Q2 earnings came out yesterday.
- TNF Pharmaceuticals (NASDAQ:TNFA) stock declined by 14.32% to $0.13. The company's market cap stands at $2.1 million.
- NeOnc Technologies (NASDAQ:NTHI) shares declined by 11.63% to $4.41. The market value of their outstanding shares is at $94.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.